Hormone Replacement Therapy (HRT)
Refer to Menopause and HRT guidance for further information, also note NICE guidance NG23 Menopause: diagnosis and management. Oral preparations are usually first-line unless not tolerated. Where patients have persistent oestrogenic side-effects, reduce dose and change preparation or move to a transdermal preparation. For patients with risk factors for venous thromboembolism or stroke consider transdermal preparations.
MHRA advice: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping (August 2019) (www.gov.uk).
For information on HRT supply shortages see:
- NHS Highland Medicines shortage log (NHS Highland intranet access required)
- Shortages information on TAM
- SPS (Specialist Pharmacy Service) Prescribing available HRT products
- British Menopause Society update on HRT supply